Equity compensation in biotech and pharma can change your financial life—sometimes on the fate of one drug

Paceline helps executives and employees at biotech and pharmaceutical companies make clearer decisions around stock options, RSUs, concentrated company stock, clinical and FDA milestones, acquisitions, and IPO lockups.

  • Turn complex equity compensation into a clear, coordinated plan

  • Make informed decisions about options, RSUs, taxes, and trading windows

  • Plan ahead of data readouts, FDA decisions, partnerships, and acquisitions

Book a call—get financial clarity

We have been featured in:

FOR BIOTECH AND PHARMA EXECUTIVES, LEADERS, AND KEY EMPLOYEES

Biotech and pharma equity is different because the opportunities—and risks—are different

Whether you're at a clinical-stage biotech, a commercial biotech, or a pharmaceutical company, equity is likely a major part of your compensation. Its value can hinge on events you don't control: trial results, FDA decisions, patent timelines, partnerships, acquisitions, and IPOs.

CLINICAL & FDA EVENTS

Your stock can move overnight on trial data

Phase 2/3 results, advisory committee meetings, and FDA decisions can reshape your net worth. We help you plan before the news, not after the stock moves.

PATENTS & COMPETITION

Even a blockbuster drug has an expiration date

Patent expirations, biosimilars, and new competitors can pressure a company that depends on one product. We help you factor these known risks into how much company stock you keep.

RSUs & CONCENTRATION

Company stock can quietly become your financial plan

Years of RSUs and options can leave most of your net worth in one stock that moves on every readout and headline. We help you decide how much to keep, what to sell, and when.

INITIAL PUBLIC OFFERINGS

A biotech IPO starts a clock, not a payday

A lockup blocks sales for months. Trading windows can also close unexpectedly around trials, financings, or deals. We help you plan early, so you're ready when a window opens.

PARTNERSHIPS & M&A

A partnership or acquisition changes your plan

A partnership can move your stock; an acquisition can cash out your equity, sometimes with milestone payments. We help you understand what you'll receive, and when.

JOB CHANGES & RETIREMENT

A career move or retirement can trigger deadlines

Leaving a company can trigger a deadline to exercise vested options and change how unvested awards are treated. We help you plan the transition early.

When biotech and pharma professionals need advice

These situations often trigger important financial decisions. We help you think through the tradeoffs with a clear plan, not just a quick answer.

A catalyst is on the calendar

A readout, FDA decision, or patent expiration is coming, and you want a plan in place before the news, not after.

Your equity has grown significantly

Your RSUs or options are now a meaningful part of your net worth, and one headline can change that quickly.

A deal or IPO may be on the horizon

Your company may be preparing for a partnership, an IPO, or a sale, and you want to be prepared for what comes next.

You're changing jobs or retiring

A new role or retirement can trigger option deadlines, affect unvested awards, and create important tax decisions.

How Paceline helps biotech and pharma professionals

We deliver practical planning for complex equity compensation, and how it fits into your broader financial situation.

Understand your equity

We help you make sense of your RSUs, options, and other equity compensation, and how they fit into your overall financial picture.

Evaluate your options

We consider different scenarios, including taxes, timing, and liquidity, so you can compare your choices with clarity.

Create a coordinated plan

We align your equity decisions with your broader financial plan, including investments, tax strategy, and lifestyle goals.

Adapt as your career evolves

As your company, role, and goals change, we help you revisit your plan and make adjustments along the way.

Articles on biotech and pharma equity planning

Practical, experience-based insights on the key decisions biotech and pharma professionals face.

  • You woke up, checked your phone, and the readout was positive. Phase 3 clinical trial data came back strong. Your employer stock has tripled in price in premarket trading. The equity you held in your company, which was one number yesterday, is a very different number this morning. It is now likely that it’s the largest financial asset you have ever owned.

    READ MORE

  • If you're a biotech employee holding employer stock through years of clinical development, waiting for an FDA approval to make your next move, you're not alone. When the outcome is binary and the financial stakes are material, that combination warrants careful planning.

    READ MORE

  • A pharma name you recognize — a big one — just signed a partnership for the molecule that you and your colleagues have spent years building. The stock price of your clinical stage biotech is up. The Slack channel is celebrating. And in the middle of registering it as good news, you probably haven't yet asked the question that actually matters for you personally.

    READ MORE

  • The IPO is done. The celebration is over. Now comes the part that actually matters — turning your stock into a lasting, life-altering windfall, or passing over an important planning opportunity.

    READ MORE

  • Your company was acquired and your equity paid out. Decide what the money is for first — then reserve for taxes, invest deliberately, and read your new grants.

    READ MORE

 

 Is one company outcome becoming
too important to your financial life?

If your biotech or pharma equity has become meaningful—or could become meaningful quickly—the right next step is a conversation about your actual grants, taxes, timing, and goals.

 

Jeremy Bohne, CFP®, CEPA
Principal & Founder

Paceline helps biotech and pharma professionals in Boston and on a remote basis by professionally managing investments and delivering financial planning. As a fee-only fiduciary, Paceline is required to place your interests first and does not accept sales commissions.

Jeremy is a Cornell MBA whose professional experience spans comprehensive financial planning, institutional investing, insurance, and management consulting. Clients value his investment expertise, listening skills, and attention to detail.